Cronos Group's stock traded lower on Tuesday, after the company reported its latest results.
The cannabis company reported revenue of C$5.6 million ($4.2 million) for the fourth quarter, up from $1.6 million a year ago. Its gross profit before fair value adjustments came in at C$2.5 million for the quarter.
For the full year, Cronos had a loss of -11 cents per share, compared to a profit of 1 cent a year earlier. Its full-year revenue of $15.7 million was higher than the previous year’s $4.1 million.
Mike Gorenstein, CEO of Cronos Group highlighted the company’s expanding presence in domestic and international markets, and its launch of iconic brands for the Canadian adult-use market. He also emphasized on the firm's research and development initiatives as well as its global partnerships. "We are proud of all we have accomplished in 2018 and in the fourth quarter. Over the past year, Cronos Group has diligently focused on our strategic objectives, which culminated in our transformative partnership with Altria Group Inc.," said Gorenstein.
Cronos shares declined more than -1% Tuesday.
The Stochastic Oscillator for CRON moved into oversold territory on March 27, 2025. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CRON advanced for three days, in of 212 cases, the price rose further within the following month. The odds of a continued upward trend are .
CRON may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on March 13, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on CRON as a result. In of 111 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for CRON turned negative on March 11, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 55 similar instances when the indicator turned negative. In of the 55 cases the stock turned lower in the days that followed. This puts the odds of success at .
CRON moved below its 50-day moving average on March 10, 2025 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CRON crossed bearishly below the 50-day moving average on March 14, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRON declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.912) is normal, around the industry mean (60.617). P/E Ratio (0.000) is within average values for comparable stocks, (90.174). CRON's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.987). Dividend Yield (0.000) settles around the average of (0.122) among similar stocks. P/S Ratio (11.481) is also within normal values, averaging (20.094).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. CRON’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
pharmaceutical, medical marijuana, cannabis
Industry PharmaceuticalsOther